42465-54-3

Basic information

• Product Name: Ethanone,1-(2-amino-3-methoxyphenyl)-
• Synonyms: Ethanone,1-(2-amino-3-methoxyphenyl)-;1-(2-Amino-3-methoxy-phenyl)-ethanone;1-(2-Amino-3-methoxyphenyl)
• CAS NO: 42465-54-3
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 165.18914
• Mol File: 42465-54-3.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 277.2 °C at 760 mmHg
• Flash Point: 130.6 °C
• Appearance: /
• Density: 1.121 g/cm³
• Vapor Pressure: 0.0046mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: Ethanone,1-(2-amino-3-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone,1-(2-amino-3-methoxyphenyl)-(42465-54-3)
• EPA Substance Registry System: Ethanone,1-(2-amino-3-methoxyphenyl)-(42465-54-3)

Safety Data

• Hazardous Substances Data: 42465-54-3(Hazardous Substances Data)

Usage

General Description

Ethanone, 1-(2-amino-3-methoxyphenyl)- is a chemical compound with the molecular formula C10H13NO2. It is also known as 2-Amino-3-methoxyacetophenone and is commonly used in the synthesis of pharmaceuticals and organic compounds. This chemical has a yellow to orange appearance and is sparingly soluble in water. It is primarily used as an intermediate in the production of various pharmaceutical drugs and is also used in research and development. Ethanone, 1-(2-amino-3-methoxyphenyl)- has potential applications in the fields of medicinal chemistry and drug discovery due to its unique chemical structure and properties.

InChI:InChI=1/C9H11NO2/c1-6(11)7-4-3-5-8(12-2)9(7)10/h3-5H,10H2,1-2H3

Upstream product

• 4502-10-7 2'-amino-3'-hydroxyacetophenone 
• 74-88-4 methyl iodide 
• 941-55-9 4-toluenesulfonyl azide 
• 586-37-8 1-(3-Methoxyphenyl)ethanone 
• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 917-54-4 methyllithium 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 15865-57-3 2-nitro-3-methoxybenzoyl chloride 
• 33852-43-6 1-(3-methoxy-2-nitrophenyl)ethanone 

Downstream Products

• 873995-53-0 2-(2-amino-3-methoxyphenyl)propan-2-ol 
• 859033-51-5 1-(2-amino-3-methoxy-phenyl)-1-phenyl-ethanol 
• 189252-16-2 1-phenyl-1-(2-amino-3-methoxyphenyl)ethylene 
• 99184-73-3 2-acetyl-6-methoxy-benzonitrile 
• 875258-00-7 acetic acid-(2-acetyl-6-methoxy-anilide) 
• 408507-83-5 formic acid-(2-acetyl-6-methoxy-anilide) 
• 228878-05-5 2-pivaloylamino-3-methoxyacetophenone 
• 950818-63-0 CH₂OC₁₄H₁₉ON 
• 950818-71-0 2-(2-amino-3-methoxyphenyl)-5,5-dimethylhex-3-yn-2-ol 
• 950818-67-4 C₁₄H₁₅ONC₂CH₂O 
• 167869-21-8 2-(2-amino-3-methoxyphenyl)chromen-4-one 
• 228878-07-7 2-(2-pivaloylamino-3-methoxyphenyl)-4H-1-benzopyran-4-one 
• 1027948-75-9 N-(2-{3-[2-(tert-butyl-dimethyl-silanyloxy)-phenyl]-3-oxo-propionyl}-6-methoxy-phenyl)-2,2-dimethyl-propionamide 
• 194782-60-0 2-isopropenyl-6-methoxy-aniline 

Relevant articles and documents

A Convenient Formal [4+2] Heterocylization Route to Bis(triflyl)tetrahydroquinolines

We report the sustainable and efficient synthesis of a new type of quinoline derivatives bearing one or two SO2CF3 groups. The protocol is metal-, catalyst- and irradiation-free, involves the use of readily available and stable precursors, and avoids the formation of side products. Also, the mild conditions of the process allow the tolerance of a wide range of functional groups.

Design, synthesis, and biological evaluation of 4-Methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases

Polypharmacology is a promising paradigm in modern drug discovery. Herein, we have discovered a series of novel PI3K and HDAC dual inhibitors in which the hydroxamic acid moiety as the zinc binding functional group was introduced to a quinazoline-based PI3K pharmacophore through an appropriate linker. Systematic structure-activity relationship studies resulted in lead compounds 23 and 36 that simultaneously inhibited PI3K and HDAC with nanomolar potencies and demonstrated favorable antiproliferative activities. Compounds 23 and 36 efficiently modulated the expression of p-AKT and Ac-H3, arrested the cell cycle, and induced apoptosis in HCT116 cancer cells. Following pharmacokinetic studies, 23 was further evaluated in HCT116 and HGC-27 xenograft models to show significant in vivo anticancer efficacies with tumor growth inhibitions of 45.8% (po, 150 mg/kg) and 62.6% (ip, 30 mg/kg), respectively. Overall, this work shows promise in discovering new anticancer therapeutics by the approach of simultaneously targeting PI3K and HDAC pathways with a single molecule.

QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS

This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The pr